Tempest Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Tempest Therapeutics, Inc. (TPST) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $6.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- Tempest Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $6.70M, a 44.89% decline from fiscal 2024.
- Tempest Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $12.16M, a 33.58% increase from fiscal 2023.
- Tempest Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $9.10M.
- Tempest Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $5.60M, a 23.29% decline from fiscal 2019.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.70M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $12.16M 10-K · filed 2026-03-30 | $12.20M 10-K · filed 2025-03-27 |
| 2023-12-31 | $9.10M 10-K · filed 2024-03-19 | |
| 2020-12-31 | $5.60M 10-K · filed 2021-03-29 | |
| 2019-12-31 | $7.30M 10-K · filed 2020-03-11 | |
| 2018-12-31 | $78.90M 10-K · filed 2019-04-01 | |
| 2017-12-31 | -$5.10M 10-K · filed 2018-03-15 | |
| 2016-12-31 | $12.30M 10-K · filed 2018-03-15 | $21.50M 10-K · filed 2017-03-02 |
| 2015-12-31 | $12.30M 10-K · filed 2017-03-02 | |
| 2014-12-31 | $19.20M 10-K · filed 2016-02-26 | |
| 2013-12-31 | $11.70M 10-K · filed 2015-03-16 | |
| 2012-12-31 | $5.00M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |